ALLMedicine™ Progressive Supranuclear Palsy Center
Research & Reviews 1,017 results
https://doi.org/10.1002/mds.29072
Movement Disorders : Official Journal of the Movement Dis... Ye R, O'Callaghan C et. al.
May 17th, 2022 - Neurodegeneration in the locus coeruleus (LC) contributes to neuropsychiatric symptoms in both Parkinson's disease (PD) and progressive supranuclear palsy (PSP). Spatial precision of LC imaging is improved with ultrahigh field 7 T magnetic resonan...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062732
NeuroImage. Clinical; Mitchell T, Wilkes BJ et. al.
May 1st, 2022 - Advanced diffusion imaging which accounts for complex tissue properties, such as crossing fibers and extracellular fluid, may detect longitudinal changes in widespread pathology in atypical Parkinsonian syndromes. We implemented fixel-based analys...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9055455
JAMA Network Open; Illán-Gala I, Nigro S et. al.
Apr 30th, 2022 - The accurate diagnosis of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) is hampered by imperfect clinical-pathological correlations. To assess and compare the diagnostic value of the magnetic resonance parkinsonism index...
https://doi.org/10.1111/jon.13001
Journal of Neuroimaging : Official Journal of the America... Riley KJ, Graner BD et. al.
Apr 27th, 2022 - The tauopathies are a heterogeneous group of neurodegenerative disorders in which the prevailing underlying disease process is intracellular deposition of abnormal misfolded tau protein. Diseases often categorized as tauopathies include progressiv...
https://clinicaltrials.gov/ct2/show/NCT04008355
Apr 26th, 2022 - A phase 2 study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 at different doses versus placebo on cerebrospinal fluid biomarkers in 36 patients with progressive supranuclear palsy. The patient study duration is 29 weeks i...
Drugs 2 results see all →
Clinicaltrials.gov 39 results
https://clinicaltrials.gov/ct2/show/NCT04008355
Apr 26th, 2022 - A phase 2 study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 at different doses versus placebo on cerebrospinal fluid biomarkers in 36 patients with progressive supranuclear palsy. The patient study duration is 29 weeks i...
https://clinicaltrials.gov/ct2/show/NCT03545126
Apr 13th, 2022 - Tauopathies are neurodegenerative diseases with tau pathology. These tauopathies are the most common pathology in neurodegenerative diseases, and they are reaching epidemic proportions. The rates of tau kinetics are central to understanding normal...
https://clinicaltrials.gov/ct2/show/NCT05320250
Apr 11th, 2022 - Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor symptoms such as bradykinesia, tremor, rigidity and postural instability. An accurate rehabilitation program designed considering the specific characteristics of the p...
https://clinicaltrials.gov/ct2/show/NCT02114242
Mar 31st, 2022 - The differential diagnosis between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy can be very difficult in early disease. PD, MSA and PSP are neurodegenerative disorders. PD and MSA belong to the alpha-synucleinopa...
https://clinicaltrials.gov/ct2/show/NCT04367116
Mar 25th, 2022 - The Study to Evaluate the Safety and Efficacy of Spinal Cord Stimulation on Progressive Supranuclear Palsy is an open-label, prospective, single-arm, unicentral and exploratory clinical trial. In the screening stage, patients clinically and radiol...
News 36 results
https://www.medpagetoday.com/neurology/generalneurology/98523
May 3rd, 2022 - Menopause status moderated sex differences in tau burden, with a divergence in tauopathy between the sexes apparent 20 years earlier than previously reported. (Annals of Neurology) Plasma p-tau was a less consistent marker of brain amyloidosis in ...
https://www.medpagetoday.com/neurology/dementia/96915
Jan 28th, 2022 - Blood-based biomarkers may help differentiate people with different dementias and monitor disease changes over time, a longitudinal study showed. Plasma markers showed different profiles in Alzheimer's disease, frontotemporal dementia, Lewy body d...
https://www.medpagetoday.com/neurology/alzheimersdisease/90555
Jan 6th, 2021 - This story was published originally on May 4, 2020. As part of MedPage Today's review of stories in the past year, we're republishing it, along with an update on further developments in blood tests for Alzheimer's disease. An ultrasensitive blood ...
https://www.medscape.com/viewarticle/922592
Dec 13th, 2019 - Topline results from the phase two PASSPORT trial show the experimental drug gosuranemab (BIIB092, Biogen) did not meet its primary or key secondary endpoints in patients with the atypical parkinsonian disorder of progressive supranuclear palsy (P...
https://www.medscape.com/viewarticle/921622
Nov 25th, 2019 - I often repeat her presentation to medical students: my only patient ever to fall walking into a clinic visit had progressive supranuclear palsy (PSP). Her impaired postural reflexes were no match for a set of brick steps. Perhaps she didn't notic...